Death, Deep Vein Thrombosis, and Toxic Reactions Leading to Impaired Kidney Function Were Side Effects in Elderly Yet Drug Manufacturer Created Separate Nursing Home Sales Force to Off-Label the Drug, According to NYC-Based National Qui Tam Whistleblowers’ Attorney Timothy J. McInnis, Esq.
(NEWARK, NJ) –For at least four years, drug manufacturer Par Pharmaceutical Companies, Inc., and its subsidiary Par Pharmaceuticals, Inc. (together “Par”) risked the lives of senior citizens across the U.S., by illegally off-label marketing to the elderly Megace ES, a prescription approved only to help HIV and cancer patients gain weight by increasing their appetite, qui tam whistleblowers’ attorney Timothy J. McInnis announced.
Read the McInnis Law News Release
Read the Par Pharmaceuticals Settlement Agreement
Read the U.S. Attorney’s News Release
The Key Relators’ Original Complaint
